Program:
Which constitutive roles of stress response molecules (SRM) are relevant to the outcome of cancer therapies?
Are the molecular responses stress and tissue specific?
What do SRM tell us about the therapy-related characteristics of tumours?
How does SRM expression in tumours compare with that in the tissue of origin?
What are the molecular responses to oxidative, hypoxic and reperfusional stresses?
To what extent do different therapeutic modalities 'precondition' each other?
How does the age of the patient/subject affect the stress response?
How can the expression of SRM be modulated and to what effect?
Registration :
Deadline for Abstracts: 18th July 1997
Email for Requests and Registration: RDBJVM@PICR.CR.MAN.AC.UK